Table 3.

Study treatment exposure, dose reduction and discontinuations by ALBI grade (safety population).

	ALBI grade 1		ALBI grade 2
	Cabozantinib (N = 186)	Placebo (N = 102)	Cabozantinib (N = 279)	Placeb (N = 133)
Median duration of exposure (range), months	4.9 (0.1–31.8)	2.1 (0.1–27.2)	3.3 (0.1–37.3)	2.0 (0.0–13.5)
Median average daily dose (range), mg	36.7 (1.1–60.0)	58.9 (21.8–60.0)	35.3 (3.9–60.0)	58.7 (12.0–60.0)
Discontinuation due to treatment-related adverse event, n (%)	23 (12)	2 (2)	52 (19)	5 (4)

ALBI albumin–bilirubin.